Staged hybrid coronary revascularization for treatment of multi-vessel coronary artery disease

张鲁锋,宋之明,杨航,凌云鹏,万峰
DOI: https://doi.org/10.3969/j.issn.1672-5301.2017.03.009
2017-01-01
Abstract:Objective This study was to investigate effect of staged hybrid revascularization as new treat-ment for multi-vessel coronary artery disease. Methods From Aug 2014 to Mar 2016,80 patients with multi-vessel coronary artery disease underwent staged hybrid coronary revascularization,which combined of minimally in-vasive direct coronary artery bypass and percutaneous coronary intervention. Perioperative data and clinic result were collected and analyzed. Results 80 patients underwent successful staged hybrid coronary revascularization with 1.5 stents per patient. 10 patients underwent PCI-first and 70 patients underwent MIDCAB-first hybrid pro-cedure. No conversion to sternotomy occurred during surgical procedure. Postoperative mechanical ventilation time was(7.3±3.1)h,mean intensive care unit stay time was(20.1±10.4)h. 75 patients(75/80,93.8%)didn′t have transfusion of blood product. Postoperative angiography showed patent LIMA to LAD graft in all patients. 1 patient developed postoperative inferior wall myocardium infarction,which was due to acute occlusion of critically stenosis in right coronary artery. He recovered well after re-open right coronary artery with percutaneous coronary stent. No death or stroke occur during hospitalization and follow up. Conclusion Staged HCR technique is a safe and effec-tive treatment for multi-vessel coronary artery disease. Surgeons and interventionists discuss together preoperatively and make strategy for staged HCR. Perioperative anticoagulation regimen is adjusted according to sequence of staged revascularization.
What problem does this paper attempt to address?